Despite weaker-than-expected interim numbers, CSL maintains “ambitious” full-year guidance. But investors are sceptical Rhythm Biosciences enlists its first prescriber for its Colostat bowel cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results